Controlled Liquid Antisolvent Precipitation of Hydrophobic Pharmaceutical Nanoparticles in a Microchannel Reactor
article
OA: closed
CC0
AI-generated summary
Liquid antisolvent precipitation in a microchannel reactor synthesized additive-free danazol nanoparticles with reduced size and enhanced dissolution rates, demonstrating the method's potential for preparing uniform hydrophobic drug particles.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Microchannel reactors are a rapidly emerging and promising technology field for their enhanced mass transfer and excellent heat exchange induced by dimensional effects. A method, the liquid antisolvent precipitation (LASP) process in a microchannel reactor (MCR), is proposed here to directly synthesize danazol nanoparticles without additives. The mean particle size decreased from 55 μm to 364 nm, and the specific surface area increased from 0.66 to 14.37 m2/g after the LASP process in MCR. The mean particle size can be facilely controlled by regulating the parameter of the MCR setup. The chemical composition and physical characteristics of the as-prepared danazol nanoparticles were demonstrated to be unchanged after processing according to FT-IR and XRD analyses. Correspondingly, the dissolution rate of the nanoparticles within 5 min was enhanced from 35% to 100% compared to the raw danazol particles. Combined with the controlled LASP method, MCR exhibits great potential for preparation of hydrophobic drugs with uniform particle size distribution in the nanometer range.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (26)
- doi:10.1081/ddc-100108363 via openalex
- doi:10.1021/la061122t via openalex
- doi:10.1016/j.cej.2006.02.011 via openalex
- doi:10.1002/adma.200305449 via openalex
- doi:10.1002/ceat.200390048 via openalex
- doi:10.1021/op010066u via openalex
- doi:10.1016/s0169-409x(00)00118-6 via openalex
- doi:10.1016/s0378-5173(02)00261-2 via openalex
- doi:10.1023/a:1021410028371 via openalex
- doi:10.1088/0960-1317/11/2/307 via openalex
- doi:10.1021/nl050097t via openalex
- doi:10.1016/s0928-0987(02)00251-8 via openalex
- doi:10.1002/ange.19300432209 via openalex
- doi:10.1021/ie010040r via openalex
- doi:10.1016/j.ijpharm.2006.05.048 via openalex
- doi:10.1016/s0378-5173(99)00412-3 via openalex
- doi:10.1002/bit.20140 via openalex
- doi:10.1016/s0040-4020(02)00432-5 via openalex
- doi:10.1021/ja01167a001 via openalex
- doi:10.1021/ja025618i via openalex
- doi:10.1021/cr030027b via openalex
- doi:10.1016/j.ces.2004.11.033 via openalex
- doi:10.1016/0009-2509(91)80035-w via openalex
- doi:10.1021/ja01084a069 via openalex
- doi:10.2533/000942902777680045 via openalex
- doi:10.1021/ja020932y via openalex
Source provenance
- openalex
- last seen: 2026-05-10T10:39:26.118035+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK